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It has been established that both medical and psychiatric out-patients
have a high prevalence of hypochondriasis and its related new
diagnosis, health anxiety.1,2 Patients attending out-patient clinics
also have a high prevalence of personality disorder, usually
between 25 and 35%, and in some cases these personality charac-
teristics could in themselves be regarded as hypochondriacal.1 In
addition, there is robust evidence that the presence of personality
disorder impairs response to treatment and worsens outcome
in depression3,4 and to a lesser extent in anxiety and obsessive–
compulsive disorders.5–8 Personality disorder has also been found
to be a predictor of higher costs in the long term among people
with depression.9 To date, there are no published studies examining
the effect of personality disorder on the outcome of health anxiety
or on the response to treatment. In the presence of personality
disorder, the benefits of cognitive–behavioural therapy (CBT)
for anxiety and depression may not be as marked as those from
antidepressant drug treatment.10,11 Hypochondriacal personality
features may also impair the outcome of common mental
disorders in the long term.12 The status of health anxiety in
current psychiatric classifications has also been a subject of debate,
particularly as the diagnosis of hypochondriasis has been removed
from DSM-5,13–15 and partly replaced by ‘illness anxiety’.16 In
ICD-11 health anxiety may or may not be a formal diagnosis in
its own right, and the diagnosis of hypochondriasis (together with
illness anxiety) could still be retained. Because of this uncertainty
we used a two-stage process of recruitment to a planned random-
ised study of psychological treatment to ensure that we recruited
those who not only had hypochondriasis but also significant
associated anxiety, so that those who were primarily depressed
and hypochondriacal were not included. At the time the trial began
there was only limited evidence of the efficacy of psychological
treatments for this condition.17 In addition, because of the strong
associations between personality disorder and anxiety, confirmed
recently in another study,18 the assessment of personality status
was included in the planned protocol. This was a randomised
controlled trial (RCT) of the cost-effectiveness of a modified form
of cognitive–behavioural therapy for health anxiety (CBT-HA).19
Two hypotheses related to personality were given in the published
protocol.19 First, that CBT-HA would be less effective in patients
who had additional personality disorder and second that such
comorbid personality disorder would be associated with increased
costs over a period of 2 years.
Method
Study design
The Cognitive behaviour therapy for Health Anxiety in
Medical Patients (CHAMP) trial was a pragmatic RCT
(ISRCTN14565822); full details of the trial are given elsewhere.19
In brief, the study recruited patients attending medical out-patient
clinics and randomised them to either 5–10 sessions of CBT-HA
(from initially naive but subsequently trained therapists) or to
standard care in primary and secondary care clinics. Patients
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Background
Health anxiety, hypochondriasis and personality disturbance
commonly coexist. The impact of personality status was
assessed in a secondary analysis of a randomised controlled
trial (RCT).
Aims
To test the impact of personality status using ICD-11
criteria on the clinical and cost outcomes of treatment
with cognitive–behavioural therapy for health anxiety
(CBT-HA) and standard care over 2 years.
Method
Personality dysfunction was assessed at baseline in
444 patients before randomisation and independent
assessment of costs and outcomes made on four
occasions over 2 years.
Results
In total, 381 patients (86%) had some personality dysfunction
with 184 (41%) satisfying the ICD criteria for personality
disorder. Those with no personality dysfunction showed
no treatment differences (P=0.90) and worse social function
with CBT-HA compared with standard care (P50.03) whereas
all other personality groups showed greater improvement
with CBT-HA maintained over 2 years (P50.001). Less benefit
was shown in those with more severe personality disorder
(P50.05). Costs were less with CBT-HA except for non-
significant greater differences in those with moderate or
severe personality disorder.
Conclusions
The results contradict the hypothesis that personality
disorder impairs response to CBT in health anxiety in both
the short and medium term.
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attending cardiology, endocrine, gastroenterology, neurology and
respiratory medicine clinics were included from six hospitals in
London, Middlesex and North Nottinghamshire. The recruitment
process was as follows: patients, with their consent, who were
attending clinics completed the short form of the Health Anxiety
Inventory (HAI),20 a self-rated scale of 14 questions with a
score range of 0–42. Those that scored 20 or more on the scale
(a point that has previously been shown to discriminate between
those who have persistent worries over health and those who show
normal variation20,21) were invited to take part in the trial and an
information sheet about the study was given. In addition, the
initial assessment involved asking key questions from the
Structured Clinical Interview for DSM-IV22 covering the formal
diagnosis of hypochondriasis. The inclusion criteria were patients
aged between 16 and 75 years, living in the area covered by the
hospital, with sufficient understanding of English to read and
complete study questionnaires and interviews, and who had given
written consent for interviews, audiotaping of 50% of treatment
sessions, and for access to their medical records.19 All those who
satisfied the inclusion criteria and hypochondriasis diagnosis were
then offered randomisation to the trial, and, if they agreed, full
baseline assessments were completed and written informed
consent obtained. This ensured a population who had anxious
hypochondriasis primarily. Follow-up data were collected at 3, 6,
12 and 24 months. The study was approved by the North
Nottingham Ethics Committee (08/H0403/56) before the start of
data collection.
Assessments
The primary outcome measure was the HAI score change from
baseline after 1 year.20 Other measures included generalised anxiety
and depression using the Hospital Anxiety and Depression Scale
(HADS-A and HADS-D),23 health-related quality of life using
the short Euroqol measure (EQ-5D),24 and social functioning
using the Social Functioning Questionnaire (SFQ).25 All measures
were recorded at baseline, 6, 12 and 24 months (with the
exception of the HAI which was also recorded at 3 months).
Assessments were made completely independently by research
assistants. Service-use data for the economic evaluation were
collected at baseline, 6-, 12- and 24-month follow-up using the
Adult Service Use Schedule (AD-SUS), a self-report instrument
assessed in interview and designed on the basis of previous
economic evaluations in adult mental health populations.26
Personality assessment was carried out using the quick version
of the Personality Assessment Schedule (PAS-Q),27 which records
both the severity and the type of personality disorder using a four-
point scale (see online supplement DS1 ). This contains a series of
screening questions for each area of personality dysfunction, and
those that score positive are asked further questions. The PAS-Q
was administered by a trained research assistant, and the assessment
forms include both numerical ratings and written comments on
each of the sections. During the course of the study the Working
Group for the Reclassification of Personality Disorder in ICD-11
completed its initial work on a new system of classification based
on severity criteria (April 2010).28 The ICD-11 classification at
that stage is summarised (Appendix). Subsequently, R.S., P.T.
and G.L. reclassified the personality status of the patients in the
study to convert them to ICD-11 severity equivalents by examining
the PAS-Q data and written comments29 as well as interviewing
assessors if the data were not clear. For 30 of the assessments
R.S. and P.T. completed independent assessments and achieved a
good level of agreement (kappa (k) = 0.84, 95% CI 0.60–1.0).
The ICD-11 classification will be published in 2017.
Randomisation and masking
Randomisation to the two treatment groups was carried out by an
independently operated computerised system (Open-CDMS),
with a computer-generated random sequence using block
randomisation with varying block sizes of four and six. The
allocation sequence was not available to any member of the
research team until databases had been completed and locked.
Statistical analysis
The calculation of the sample size for the main study has been
described previously;19 it was powered to assess the superiority
of CBT-HA over standard care after 1 year, with the HAI score
as the main outcome measure. The current study was a secondary
analysis of the outcomes for different levels of severity of
personality disturbance and so no formal sample size calculation
was performed. The primary end-point (HAI) was analysed using
a mixed model with time, treatment group and time6treatment
interaction as fixed effects, baseline measurement as covariate
and patient as random effect by personality severity group in
order to test for the first hypothesis, that the CBT-HA would
be less effective in participants with a personality disorder. The
treatment differences between the four ICD-11 personality groups
were calculated at each time point (3 months for HAI only), 6
months, 1 year and 2 years). Other secondary end-points were
analysed in the same way. All analyses were based on the
intention-to-treat principle. At baseline, continuous data were
expressed as means and standard deviations and compared using
analysis of variance (ANOVA). Categorical data were summarised
using number (%) and compared using chi-squared tests.
Economic analysis
The planned economic evaluation is described in detail elsewhere.19
Total costs were calculated by combining the service-use data
collected from the AD-SUS together with hospital use from
electronic records with nationally applicable unit costs.30–32 Costs
were calculated and analysed in UK pound sterling for the financial
year 2008–2009 and were discounted in the second year at a rate
of 3.5% as recommended by the National Institute for Health
and Care Excellence.33 Complete case analysis was used for the
economic evaluation.19 The second hypothesis, that participants
with personality disorder would have increased costs was explored
through the examination of differences in costs over the 24-month
follow-up period between ICD-11 groups. Analysis was performed
using ordinary-least-squares regression as is appropriate for cost
data, with the robustness of the tests confirmed using bias-
corrected, non-parametric bootstrapping.34,35 Differences in all
analyses were adjusted for baseline costs and randomised group.
We tested for differences between complete cases and missing
cases using key baseline characteristics and found no significant
difference between groups – only the complete cases appear in
the analysis.
Results
In total, 445 patients were randomised in the study but one
patient was referred and randomised twice – both times to the
standard care group – and the first date was taken for inclusion.
All 444 patients had their personality status assessed at baseline
(Appendix). Nine patients died during the study, six in the
standard care group, three in the CBT-HA group. Of the patients
who died one had no personality dysfunction, four had personality
difficulty, one had mild personality disorder and three had moderate
personality disorder.
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Personality status and cognitive–behavioural therapy for health anxiety
Using the ICD-11 classification only 63 (14.2%) had no
personality dysfunction but 197 (44.3%) had personality difficulty
(a subthreshold condition not qualifying for disorder). Only three
people assessed had severe personality disorder and so they were
included with the moderate group as their numbers were too
low for analysis. No differences in patient characteristics at base-
line were identified and there was an even spread of men and
women and a similar age profile between the ICD-11 personality
groups (Table 1). However, there were significant differences in
symptoms of health anxiety and generalised anxiety, depression
and social functioning at baseline; participants with moderate to
severe personality disorder had significantly higher scores than
those with no personality disturbance (Table 1). There were no
differences in total cost at baseline.
The outcome data over follow-up by ICD-11 classification are
detailed in Table 2 and in Fig. 1. Contrary to our hypotheses the
results show that those with no personality dysfunction showed no
benefit from CBT-HA compared with standard care at any time
point in the study; overall, standard care was superior for the
symptoms of anxiety and depression (P50.01) and for social
functioning (P50.05) but not for health anxiety. For all other
groups the picture was different. For participants with personality
difficulty and mild personality disorder, there was evidence of
much stronger reduction in health anxiety in the CBT-HA group
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Table 1 Patient characteristics, clinical ratings and cost at baseline by ICD-11 personality levela
Personality level
0
(n=63)
1
(n=197)
2
(n=142)
3–4
(n=42)
Statisticsb
P
Gender, n (%)
Female 29 (46.0) 109 (55.3) 76 (53.5) 22 (52.4) 0.642
Male 34 (54.0) 88 (44.7) 66 (46.5) 20 (47.6)
Age, years
Mean (s.d.) 48.6 (14.8) 49.5 (13.6) 47.5 (13.6) 47.9 (11.3) 0.592
Minimum–Maximum 18.3–73.9 17.3–74.3 17.0–75.5 21.7–72.4
Health Anxiety Inventory, mean (s.d.) 24.0 (3.2) 24.8 (4.5) 25.2 (4.3) 26.9 (4.9) 0.006
Hospital Anxiety and Depression Scale, Anxiety: mean (s.d.) 10.1 (3.6) 12.1 (3.7) 13.4 (3.6) 14.0 (3.6) 50.001
Hospital Anxiety and Depression Scale, Depression: mean (s.d.) 6.7 (3.7) 8.2 (4.1) 10.0 (4.4) 12.4 (4.7) 50.001
Social Functioning Questionnaire, mean (s.d.) 5.9 (3.4) 8.6 (4.0) 11.3 (4.4) 12.7 (3.8) 50.001
Total cost (preceding 6 months), mean (s.d.) 2405.2 (2526.3) 2601.8 (2837.2) 2668.1 (2887.1) 2692.5 (2708.3) 0.954
a. Where 0, no personality dysfunction; 1, personality difficulty; 2, mild personality disorder; 3, moderate personality disorder; and 4, severe personality disorder.
b. w2 for gender differences, ANOVA for others.
Table 2 Summary changes from baseline in the cognitive–behavioural therapy for health anxiety (CBT-HA) group compared with
standard care in ICD-11 personality groupsa
ICD-11 personality level, difference (95% CI)
0 (n=63) 1 (n=197) 2 (n=142) 3 and 4 (n=42)
Health Anxiety Inventory scores
3 month 2.12 (71.41 to 5.64) 71.62 (73.56 to 0.31) 73.24** (75.57 to 70.92) 73.76 (78.24 to 0.71)
6 month 71.29 (74.9 to 2.31) 74.80*** (76.77 to 72.84) 75.51*** (77.85 to 73.16) 78.13** (712.59 to 73.66)
12 month 0.47 (73.11 to 4.05) 73.55** (75.54 to 71.57) 73.32** (75.69 to 70.96) 74.42 (78.99 to 0.14)
24 month 1.45 (72.12 to 5.03) 72.98** (74.98 to 70.97) 72.96* (75.35 to 70.56) 70.31 (74.93 to 4.31)
At all time points 0.69 (72.23 to 3.6) 73.24*** (74.84 to 71.64) 73.76*** (75.78 to 71.74) 74.16* (77.99 to 70.33)
Hospital Anxiety and Depression
Scale, anxiety scores
6 month 1.45 (70.5 to 3.39) 71.47* (72.64 to 70.29) 71.71* (73.05 to 70.36) 72.03 (74.7 to 0.65)
12 month 2.68 (0.75 to 4.62) 71.70** (72.89 to 70.51) 71.42* (72.78 to 70.06) 71.32 (74.05 to 1.41)
24 month 2.21* (0.25 to 4.16) 71.81** (73.01 to 70.60) 71.00 (72.38 to 0.38) 71.00 (73.77 to 1.77)
At all time points 2.11** (0.51 to 3.71) 71.66*** (72.62 to 70.70) 71.38* (72.56 to 70.20) 71.45 (73.79 to 0.89)
Hospital Anxiety and Depression
Scale, depression scores
6 month 2.17* (0.11 to 4.24) 71.33* (72.49 to 70.17) 71.1 (72.49 to 0.28) 71.42 (74.32 to 1.48)
12 month 1.79 (70.27 to 3.85) 71.27* (72.45 to 70.09) 70.69 (72.10 to 0.71) 72.64 (75.62 to 0.33)
24 month 3.29** (1.22 to 5.36) 70.69 (71.88 to 0.49) 71.84* (73.27 to 70.41) 72.06 (75.08 to 0.96)
At all time points 2.42** (0.62 to 4.21) 71.10* (72.06 to 70.13) 71.21* (72.41 to 70.02) 72.04 (74.55 to 0.47)
Social Functioning
Questionnaire scores
6 month 2.32* (0.19 to 4.45) 70.42 (71.57 to 0.73) 70.31 (71.68 to 1.06) 71.89 (74.54 to 0.77)
12 month 1.52 (70.61 to 3.64) 70.08 (71.25 to 1.09) 70.66 (72.05 to 0.73) 71.91 (74.64 to 0.82)
24 month 2.88** ( 0.75 to 5.01) 70.19 (71.37 to 0.98) 71.49* (72.9 to 70.08) 70.88 (73.65 to 1.89)
At all time points 2.24* (0.41 to 4.07) 70.23 (71.19 to 0.73) 70.82 (71.97 to 0.33) 71.56 (73.83 to 0.71)
a. All minus scores indicate greater improvement in CBT-HA group except for social functioning (SFQ)). All analyses used a mixed-model approach with time, treatment group and
time6treatment interaction as fixed effects, baseline measurement as covariate, and patient as random effect by personality severity group. ICD-11 personality level: 0, no
personality dysfunction; 1, personality difficulty; 2, mild personality disorder; 3, moderate personality disorder; and 4, severe personality disorder. Full details of all scores are
shown in online Table DS274.
*P50.05, **P50.01, ***P50.001.
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at all time points compared with standard care (P50.001). For
participants with moderate and severe personality disorder the
initial benefit was not retained at 2 years resulting in a less strong
relationship over follow-up (P50.05). Clinical symptomatology
increased and social dysfunction was greater with each increment
of personality pathology (Table 1). The differences in scores
between treatment groups were most marked for health anxiety;
similar, but lower, differences were found for generalised anxiety
and depressive symptoms (Table 2).
Total costs over 24-month follow-up by randomised group
and personality score are detailed in Table 3. Costs were broadly
similar across groups, although highest in those with personality
dysfunction and lowest in those with moderate to severe personality
disorder. Regression analysis showed that the differences in cost
between groups fell well short of significance.
Discussion
Surprising nature of findings
The challenging finding of this study was that both the hypotheses
concerning personality status were soundly contradicted. These
results should be seen in the context of the main primary aim
of the trial; in the analysis of outcomes independently of
personality status CBT-HA was markedly superior to standard
care with respect to clinical symptoms of anxiety (and to some
extent depression) but no marked changes were found in social
function.36 People with no personality dysfunction did not
benefit from CBT-HA and as their social functioning deteriorated
with CBT this treatment cannot be regarded as effective in this
population. By contrast those with any form of personality
abnormality (personality difficulty, mild or moderate personality
disorder) did benefit from CBT-HA and their improvement was
maintained over 2 years except in those with moderate or severe
personality disorder. Such a finding has not been reported before
and as it contradicted our main hypothesis (with the possible
exception of worse outcome in more severe personality disorder)
other explanations need to be considered before it can be accepted
as valid.
In the report from the original trial36 the costs were equivalent
in both treatment groups and no clear saving was made with
CBT-HA. A large part of the costs was taken up with the care of
patients with severe medical illness and this may have disguised
any savings made by CBT-HA. Nonetheless, the costs were less,
but not significantly so, in all groups receiving CBT-HA compared
with standard care, with the exception of those with moderate and
severe personality disorder who cost more in the CBT-HA group
(mean £1166) (Table 3). This suggests the possibility that for those
who have moderate or severe personality disorder there is a greater
cost with CBT-HA, for reasons that are not completely clear but
seem to be independent of medical status, and, as suggested in a
previous paper,37 may be related to poorer social function.
4
Treatment
CBT-HA
Standard
Personality severity score = 0 Personality severity score= 1
Personality severity score = 2 Personality severity score= 3–4
0 6 12 18 24
Month
0 6 12 18 24
0.0 –
72.5 –
75.0 –
77.5 –
710.0 –
0.0 –
72.5 –
75.0 –
77.5 –
710.5 –
M
ai
n
ch
an
ge
in
H
A
I
sc
o
re
Fig. 1 Mean change in scores on the short form of the Health Anxiety Inventory (HAI) separated by personality status.
Personality severity scores: 0, no personality dysfunction (n= 63); 1, personality difficulty (n=197); 2, mild personality disorder (n=142); 3–4, moderate and severe personality
disorder (n=42).
Personality status and cognitive–behavioural therapy for health anxiety
A qualifying comment is necessary here, as in the trial a large
proportion of those screened did not agree to take part in the
trial.36 It could be argued that the 444 patients seen were not
therefore representative of the total population.
ICD-11 classification of personality disorder
It is worth emphasising that this is the first study to report on the
effect of personality status using the new ICD-11 coding and so
there are no other studies with which this one can be compared.
The small number of patients with no personality dysfunction
(n= 63) may appear surprising but there are other data suggesting
that when personality difficulty is taken into account this
subsyndromal group accounts for a large proportion of the
total.38–41 Patients with health anxiety commonly have symptoms
for many years before they present for treatment41 and people
with chronic anxiety conditions have a high prevalence of
personality disorder42 and so the overall prevalence of personality
disorder of 42% in this sample is in keeping with other figures. It
is also important to stress that the diagnosis of core personality
disorder is very little different in ICD-11 from ICD-10, but the
great flexibility in diagnosis across the lifespan tends to increase
prevalence.40 Only one other study has examined the effect of
personality status on the outcome of health anxiety and
hypochondriasis and this is not directly comparable with our data.
This was a follow-up of an RCT of paroxetine, placebo, CBT
and those who dropped out. In total, 60% were followed up
successfully and those who had less harm avoidance and were more
cooperative had a better outcome.43 No analysis by treatment group
was made.
It also could be argued in our study that a proportion of the
population may have been misdiagnosed with health anxiety and
this could be explained by the cut-off of 20 points on the HAI as
being too low. This score equates to around 62 on the long version
of the HAI, and a score of 67 on the long HAI has been found to
be a good cut-off point for discriminating between severe and less
severe health anxiety.44 But as all patients satisfied the criteria for
hypochondriasis it is unlikely the level of health anxiety was too
low. The requirement for high scores on health anxiety and the
diagnosis of hypochondriasis would only exclude patients with a
primary depression component to their symptoms. Third, it could
be argued that the patients with no personality dysfunction had
appropriate health anxiety because of incipient and concurrent
significant medical illness but this view is not supported by the
figures as the costs were lower in those with no personality
dysfunction compared with those with personality difficulty and
personality disorder, although none of these differences was
statistically significant.
It is also fair to add that the ICD-11 classification of
personality disorder is not yet approved by the World Health
Organization and more is currently being done to confirm the
cut-off points for the levels of personality disturbance.45 The
fundamental structure of the reclassification is nonetheless very
likely to be approved. The version of the ICD-11 classification
used in the study28 shows some slight differences to the current
version, but not to any substantive degree. It is also worth
pointing out that if the analysis of this study had been carried
out using the old ICD-10 diagnostic system of ‘personality
disorder’ v. ‘no personality disorder’, it is unlikely that these
important differences would have been found, as the markedly
positive value of CBT-HA in mild personality disorder and
personality difficulty would have been split between the groups.
There are also other suggestions that personality status may
improve during the course of psychological treatment for
health anxiety, and although one needs to be aware of the well-
established evidence that standard personality measures tend to
improve as mood improves46 there are some reasons to think that
the change is more substantial.47
Implications for treatment
Taken together, but subject to further replication studies, it is
reasonable to suggest that in the absence of personality
dysfunction CBT-HA is an inappropriate treatment for health
anxiety. It also implies that an assessment of personality status is
necessary in the evaluation of people with suspected pathological
health anxiety, as those without any personality disturbance
may be much more appropriately treated, as at present, with
reassurance and support rather than formal psychological inter-
vention. The findings also give some clinical credence to the
notion of a subsyndromal form of personality dysfunction in
the form of personality difficulty, as the differences in outcome
between this group and those with no personality dysfunction
were so different.
In contrast with studies in depression and anxiety,9 we found
little evidence that personality disorder had an impact on service
use and cost. The results in terms of costs present a mixed picture,
one which reflects those of the main study. Clear conclusions
regarding differences in cost are difficult to make in this group
because, irrespective of health anxiety and personality status,
study participants often had substantial physical health problems
that result in substantial levels of service use and therefore
high costs. The relative influence of personality on service-use
behaviour may therefore be limited. Previously reported evidence
of greater service use at all levels of services in patients with
personality disorder, especially at levels of greater severity,38 is
slightly at variance with our findings, which showed lower costs
in more severe personality disorder, again illustrating the likely
impact of comorbid medical conditions on total cost.
Clinical psychiatry has not yet embraced the importance of
twin assessments of mental state and personality status when
deciding on treatment but this study, and others across a wide
range of conditions3–8,10,11,48,49 suggest that better judgements
can be made when personality status is given as much importance
as mental state in clinical practice.
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Table 3 Total costs over 24-month follow-up by randomised group and personality level
ICD-11 personality score
CBT-HA, mean
(s.d.)
Treatment as usual,
mean (s.d.) Total, mean (s.d.)
Adjusted mean
difference (95% CI) P
No personality disorder, 0 (n=44) 6386.5 (5858.1) 7853.0 (10422.2) 7153.05 (8490.27) 71232.8 (76215.66 to 3749.89) 0.620
Personality difficulty, 1 (n=134) 7215.8 (8140.8) 8155.8 (9075.8) 7657.76 (8573.20) 7380.1 (73167.13 to 2406.93) 0.788
Mild personality disorder, 2 (n=86) 6792.7 (5739.6) 7667.0 (10012.3) 7657.77 (8573.20) 471.8 (72377.20 to 3300.87) 0.747
Moderate and severe personality
disorder, 3+4 (n=23) 6610.2 (3392.4) 5391.8 (3545.6) 6080.48 (3435.36) 1262.4 (71869.75 to 4394.54) 0.410
CBT-HA, cognitive–behavioural therapy for health anxiety.
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Online supplement DS1 
The Quick Personality Assessment Schedule (PAS-Q) was the main personality database used in the 
CHAMP study and the ICD-11 diagnoses were derived from these data together with assessment of 
the written notes made for each patient.  This online supplement contains relevant information 
about the PAS-Q and the outcomes in the trial separated by its levels of personality dysfunction.     
The PAS-Q is a quick form of the Personality Assessment Schedule (PAS)50 that is carried out by 
assessors who have already been trained in the full PAS.  The aim of the PAS and PAS-Q is to identify 
personality features that are enduring and independent of any current mental illness.  The more 
information that is available about a patient the less likely is the assessment to be distorted by any 
current mental health problems.  If little or no information exists it is suggested that the following 
probing questions be asked before passing on to the main questions involved in the PAS-Q.  The 
following procedure is suggested but this could be modified and changed under the circumstances of 
the interview and with the individuals concerned.  
I should like to find out what sort of person you were like before your present problems began.  
Could you tell me in a few words how you would describe yourself in this respect?  (record 
response) 
I wonder if you could tell me a bit more information about yourself.  Are you married or have you 
ever been married?  Have you any children?  Where are they living now? 
(elucidate to what extent relationships have been unstable and whether there have been any 
difficulties in close relationships.  This will also determine whether the person has any interest in 
close relationships) 
Are you working at present, if not, when was the last time you were in work? 
What are the jobs you have been mainly involved in since leaving school? 
What were the circumstances in which you lost your last job(s)? 
Have you ever been in trouble with the law?  What was the problem?  Were you arrested? 
Have you ever had any problems with alcohol or drugs? 
Have you ever felt that these take over your life and you can’t control them? 
Do you gamble?  Has this been a problem? 
How many times have you moved house in the last 10 years? 
What were the reasons for moving? 
Have you ever been homeless? 
 
PAS-Q Screening Questions:  The full PAS includes screening questions which then lead on to other 
questions which eventually lead to a scoring of the characteristics in question.  In the PAS-Q only the 
screening questions are asked initially, and this shortens the interview to between 20 and 45 
minutes.  In deciding whether the question is being answered honestly please take into account the 
information derived from the questions asked above.  It is appreciated that on many occasions the 
screening question may lead to a positive response which then turns out to be negative when 
further questions are asked, but if  the answer is clearly negative the next screening question is 
asked. 
Example:  
How well in general do you get on with other people? 
Do you normally trust them or are you suspicious of them, at least at first? 
How long does it normally take for you to get know people before you trust them? 
If any of these answers to these questions suggests abnormal suspiciousness further questions from 
the full Personality Assessment Schedule are asked. Each main section is scored 0, 1, or 2, with 2 
constituting personality disorder.  The final assessment of personality level is decided by the 
following: 
0 = all scores zero (no personality dysfunction) 
1 = personality difficulty  
2 = personality disorder in one personality cluster (equivalent to DSM Clusters A, B and C) only – mild 
personality disorder 
3 = personality disorder in more than one cluster (moderate personality disorder) 
For the ICD-11 classification those with a score of 3 who had significant risk of harm to self or others 
were assessed separately with information derived from the written comments of the assessors. The 
algorithm for the ICD-11 classification came from the 2011 revision of the classification.28 
The main outcomes using the PAS-Q assessments are in Table DS1. 
Additional reference 
50 Tyrer P, Alexander J.  Classification of personality disorder.   Br J Psychiatry 1979; 135: 163–7. 
  
 PAS-Q Status 
  0 (n=46) 1 (n=246) 2 (n=111) 3&4 (n=41) 
HAI scores  Difference [95% CI] 
Difference 
[95% CI] 
Difference  
[95% CI] 
Difference 
 [95% CI] 
 3 month 0.58 [ -3.48 to 4.63] 
-1.71* 
[-3.39 to -0.02] 
-2.71 
[-5.56 to 0.14] 
-3.10 
[-8.37 to 2.18] 
 6 month -0.49 [-4.67 to 3.70] 
-4.89*** 
[-6.6 to -3.18] 
-5.87*** 
[-8.74 to -3.00] 
-7.25** 
[-12.54 to -1.95] 
 12 month -1.03 [-5.22 to 3.16] 
-3.13*** 
[-4.86 to -1.41] 
-2.96* 
[-5.86 to -0.05] 
-4.1 
[-9.41 to 1.21] 
 24 month 0.28 [ -3.93 to 4.49] 
-2.48** 
[-4.22 to -0.74] 
-2.93 
[-5.87 to 0.01] 
0.93 
[-4.51 to 6.38] 
 At all time points -0.16 [-3.46 to 3.13] 
-3.05*** 
[-4.46 to -1.65] 
-3.62** 
[-6.13 to -1.10] 
-3.38 
[-7.98 to 1.23] 
HADS-A scores  
 6 month 1.050 [-1.34 to 3.43] 
-1.47** 
[-2.48 to -0.46] 
-1.67 
[-3.36 to 0.02] 
-1.99 
[-4.84 to 0.86] 
 12 month 0.59 [-1.80 to 2.98] 
-1.16* 
[-2.18 to -0.14] 
-1.52 
[-3.24 to 0.20] 
-0.95 
[-3.82 to 1.92] 
 24 month 0.87 [-1.53 to 3.26] 
-0.99 
[-2.02 to 0.05] 
-2.05* 
[-3.79 to -0.31] 
-0.92 
,[-3.88 to 2.03] 
 At all time points 0.83 [-1.03 to 2.70] 
-1.21** 
[-2.05 to -0.36] 
-1.75* 
[-3.23 to -0.27] 
-1.29 
[-3.80 to 1.23] 
HADS-D scores  
 6 month 2.16 [-0.39 to 4.72] 
-0.88 
[-1.92 to 0.16] 
-1.51 
[-3.15 to 0.13] 
-1.53 
[-4.41 to 1.35] 
 12 month 1.09 [-1.47 to 3.65] 
-0.64 
[-1.69 to 0.42] 
-1.31 
[-2.99 to 0.36] 
-1.86 
[-4.75 to 1.02] 
 24 month 2.5 [-0.07 to 5.07] 
-0.52 
[-1.58 to 0.54] 
-2.03* 
[-3.72 to -0.33] 
-1.43 
[-4.43 to 1.57] 
 At all time points 1.92 [-0.31 to 4.14] 
-0.68 
[-1.55 to 0.19] 
-1.62* 
[-3.05 to -0.18] 
-1.61 
[-4.03 to 0.81] 
SFQ scores   
 6 month 2.59 [-0.38 to 5.57] 
-0.44 
[-1.43 to 0.55] 
-0.22 
[-1.78 to 1.34] 
-1.23 
[-4.09 to 1.63] 
 12 month 0.86 [-2.13 to 3.85] 
0.12 
[-0.88 to 1.13] 
-0.9 
[-2.49 to 0.69] 
-1.38 
[-4.24 to 1.48] 
 24 month 3.59
* 
[0.61 to 6.58] 
-0.46 
[-1.48 to 0.56] 
-1.21 
[-2.82 to 0.41] 
-0.92 
[-3.90 to 2.06] 
 At all time points 2.35 [-0.35 to 5.05] 
-0.26 
[-1.08 to 0.56] 
-0.78 
[-2.09 to 0.54] 
-1.18 
[-3.56 to 1.20] 
Table DS1. Summary results from mixed model analysis of change in outcome measures 
from baseline in the CBT-HA group compared to standard care (Analysis by PAS-Q) 
+      not significant                             *    P<0.05                                **    P<0.01                              *** P<0.001 
 
  
  
 
ICD 
score Visit Statistics 
Treatment A 
(N=219) 
Treatment B 
(N=225) 
All 
(N=444) 
ICD-
11 
level 
Visit Statistics CBT-HA 
group 
Standard 
Care group 
All 
0 Baseline n,mean(SD) 29,24.0(3.6) 34,24.0(3.0) 63,24.0(3.2) 
 3 Months n,mean(SD) 27,21.3(7.5) 31,19.1(5.6) 58,20.1(6.6) 
 6 Months n,mean(SD) 25,19.5(6.8) 29,20.3(6.5) 54,20.0(6.6) 
 12 Months n,mean(SD) 26,20.2(7.8) 29,19.7(6.8) 55,19.9(7.2) 
 24 Months n,mean(SD) 27,19.3(7.2) 28,18.0(7.6) 55,18.6(7.4) 
1 Baseline n,mean(SD) 100,24.6(4.2) 97,24.9(4.9) 197,24.8(4.5) 
 3 Months n,mean(SD) 94,20.5(7.9) 93,22.0(6.6) 187,21.2(7.3) 
 6 Months n,mean(SD) 89,16.8(8.3) 90,21.7(6.7) 179,19.3(7.9) 
 12 Months n,mean(SD) 86,17.6(7.5) 86,21.3(7.4) 172,19.4(7.7) 
 24 Months n,mean(SD) 85,18.2(8.2) 81,21.5(7.4) 166,19.8(8.0) 
2 Baseline n,mean(SD) 68,24.9(4.1) 74,25.5(4.5) 142,25.2(4.3) 
 3 Months n,mean(SD) 63,19.8(7.0) 69,23.9(6.6) 132,21.9(7.1) 
 6 Months n,mean(SD) 63,18.1(7.5) 65,24.0(6.0) 128,21.1(7.3) 
 12 Months n,mean(SD) 62,18.7(8.1) 61,22.5(7.8) 123,20.6(8.1) 
 24 Months n,mean(SD) 60,18.7(7.2) 57,22.5(7.1) 117,20.5(7.4) 
3,4 Baseline n,mean(SD) 22,27.1(5.3) 20,26.7(4.6) 42,26.9(4.9) 
 3 Months n,mean(SD) 21,21.5(8.9) 19,24.2(7.8) 40,22.8(8.4) 
 6 Months n,mean(SD) 20,18.1(9.6) 20,25.7(8.8) 40,21.9(9.9) 
 12 Months n,mean(SD) 20,19.2(9.2) 17,22.6(7.2) 37,20.8(8.4) 
 24 Months n,mean(SD) 18,21.7(9.9) 17,22.3(9.9) 35,22.0(9.7) 
 
                         Table DS2. Mean scores on the Health Anxiety Inventory (HAI) in  
                          CBT-HA and Standard Care groups over 24m separated by ICD-11 personality status  
0 = no personality dysfunction, 1 = personality difficulty, 2 = mild personality disorder,  
3 = moderate and severe personality disorder   
  
 
 
ICD 
level Variable Visit Statistics 
Treatment A 
(N=219) 
Treatment B 
(N=225) 
All 
(N=444) 
0 Anxiety Total Score Baseline n,mean(SD) 29,9.6(3.4) 34,10.6(3.7) 63,10.1(3.6) 
  6 Months n,mean(SD) 25,10.1(4.3) 29,9.4(4.4) 54,9.7(4.3) 
  12 Months n,mean(SD) 26,9.9(4.1) 29,8.2(4.4) 55,9.0(4.3) 
  24 Months n,mean(SD) 26,9.1(4.0) 27,8.3(4.7) 53,8.7(4.3) 
 Depression Total Score Baseline n,mean(SD) 29,6.4(3.4) 34,6.9(4.0) 63,6.7(3.7) 
  6 Months n,mean(SD) 25,7.6(4.6) 29,5.4(3.9) 54,6.4(4.3) 
  12 Months n,mean(SD) 26,7.7(5.2) 29,6.2(4.6) 55,6.9(4.9) 
  24 Months n,mean(SD) 26,8.0(5.2) 27,5.7(5.4) 53,6.8(5.4) 
1 Anxiety Total Score Baseline n,mean(SD) 100,12.7(3.4) 97,11.5(3.9) 197,12.1(3.7) 
  6 Months n,mean(SD) 89,9.3(4.7) 90,10.4(4.0) 179,9.8(4.4) 
  12 Months n,mean(SD) 86,9.0(4.1) 85,10.3(4.0) 171,9.6(4.1) 
  24 Months n,mean(SD) 85,8.6(4.4) 81,10.1(4.5) 166,9.3(4.5) 
 Depression Total Score Baseline n,mean(SD) 100,8.3(3.9) 97,8.1(4.3) 197,8.2(4.1) 
  6 Months n,mean(SD) 89,6.8(4.4) 90,7.9(4.1) 179,7.4(4.3) 
  12 Months n,mean(SD) 86,6.7(4.5) 85,7.8(4.5) 171,7.3(4.5) 
  24 Months n,mean(SD) 85,7.4(5.2) 81,7.9(5.0) 166,7.6(5.1) 
2 Anxiety Total Score Baseline n,mean(SD) 68,13.3(3.6) 74,13.4(3.7) 142,13.4(3.6) 
  6 Months n,mean(SD) 63,10.1(5.0) 65,11.9(3.8) 128,11.0(4.5) 
  12 Months n,mean(SD) 62,10.7(4.6) 61,11.8(4.2) 123,11.2(4.4) 
  24 Months n,mean(SD) 60,10.0(4.4) 56,10.7(4.8) 116,10.3(4.6) 
 Depression Total Score Baseline n,mean(SD) 68,10.6(4.4) 74,9.6(4.3) 142,10.0(4.4) 
  6 Months n,mean(SD) 63,9.1(5.0) 65,9.6(5.0) 128,9.3(5.0) 
  12 Months n,mean(SD) 62,9.3(5.4) 61,9.3(4.7) 123,9.3(5.0) 
  24 Months n,mean(SD) 60,8.2(5.1) 56,9.3(5.0) 116,8.7(5.1) 
3,4 Anxiety Total Score Baseline n,mean(SD) 22,13.7(4.2) 20,14.4(2.9) 42,14.0(3.6) 
 Clinical variable Visit Statistics CBT-HA 
group 
Standard 
care group 
All 
  6 Months n,mean(SD) 20,10.3(4.4) 20,12.8(4.9) 40,11.5(4.7) 
  12 Months n,mean(SD) 20,10.6(5.5) 17,11.5(4.8) 37,11.0(5.1) 
  24 Months n,mean(SD) 18,10.2(4.0) 17,11.4(5.2) 35,10.7(4.6) 
 Depression Total Score Baseline n,mean(SD) 22,11.8(4.3) 20,13.0(5.1) 42,12.4(4.7) 
  6 Months n,mean(SD) 20,9.2(4.6) 20,11.2(4.9) 40,10.2(4.8) 
  12 Months n,mean(SD) 20,9.2(5.4) 17,11.9(5.7) 37,10.4(5.7) 
  24 Months n,mean(SD) 18,8.8(5.1) 17,11.2(5.7) 35,10.0(5.5) 
 
                         Table DS3. Mean scores on the Hospital Anxiety and Depression Scale (HADS) in  
                          CBT-HA and Standard Care groups over 24m separated by ICD-11 personality status  
0 = no personality dysfunction, 1 = personality difficulty, 2 = mild personality disorder,  
3 = moderate and severe personality disorder   
  
 
 
ICD-
11 
level 
Visit Statistics CBT-HA 
group 
Standard 
care group 
All 
0 Baseline n,mean(SD) 29,0.0(0.0) 34,0.0(0.0) 63,0.0(0.0) 
 6 Months n,mean(SD) 25,2.8(4.7) 29,-0.1(3.8) 54,1.3(4.5) 
 12 Months n,mean(SD) 26,1.6(4.5) 29,-0.3(4.0) 55,0.6(4.3) 
 24 Months n,mean(SD) 27,1.9(4.0) 27,-1.4(3.6) 54,0.2(4.1) 
1 Baseline n,mean(SD) 100,0.0(0.0) 97,0.0(0.0) 197,0.0(0.0) 
 6 Months n,mean(SD) 89,-0.7(4.5) 90,-0.5(3.5) 179,-0.6(4.0) 
 12 Months n,mean(SD) 86,-0.5(4.4) 85,-0.7(3.6) 171,-0.6(4.0) 
 24 Months n,mean(SD) 85,-1.0(4.7) 81,-0.9(3.6) 166,-1.0(4.2) 
2 Baseline n,mean(SD) 68,0.0(0.0) 74,0.0(0.0) 142,0.0(0.0) 
 6 Months n,mean(SD) 63,-0.8(3.5) 65,-0.4(3.6) 128,-0.6(3.6) 
 12 Months n,mean(SD) 62,-1.3(4.3) 61,-0.3(3.6) 123,-0.8(4.0) 
 24 Months n,mean(SD) 60,-2.2(4.9) 57,-0.5(4.1) 117,-1.4(4.6) 
3,4 Baseline n,mean(SD) 22,0.0(0.0) 20,0.0(0.0) 42,0.0(0.0) 
 6 Months n,mean(SD) 20,-1.9(4.9) 20,-0.2(4.5) 40,-1.1(4.7) 
 12 Months n,mean(SD) 20,-1.3(4.6) 17,0.6(3.7) 37,-0.4(4.3) 
 24 Months n,mean(SD) 18,-1.7(3.9) 17,-0.7(4.3) 35,-1.2(4.1) 
 
               Table DS4. Mean scores on the Social Functioning Questionnaire (SFQ) in  
                          CBT-HA and Standard Care groups over 24m separated by ICD-11 personality status  
0 = no personality dysfunction, 1 = personality difficulty, 2 = mild personality disorder,  
3 = moderate and severe personality disorder   
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